MEDICINE DETAILS
Imjudo
Active ingredient: Tremelimumab
Neutral reference profile for an independent medicine-access consultancy enquiry about Imjudo (Tremelimumab). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Imjudo used for?
Imjudo (tremelimumab) is a human monoclonal antibody (mAb), in combination with Imfinzi (durvalumab), also a human mAb, for treating adult patients with unresectable hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Imjudo identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
20 mg/ml (25 mg total) infusion concentrate · 1.25 ml Catalogue organisation: AstraZeneca GmbH GB Spezialvertrieb
-
20 mg/ml (300 mg total) infusion concentrate · 15 ml Catalogue organisation: AstraZeneca GmbH GB Spezialvertrieb
OFFICIAL SOURCES
Check the Imjudo record at an official source.
Search for “Imjudo” or “Tremelimumab”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Imjudo.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Imjudo
01What is Imjudo?＋
This directory record associates the brand name Imjudo with the active ingredient Tremelimumab. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Imjudo strengths and packs are recorded?＋
The catalogue currently shows: 20 mg/ml (25 mg total) infusion concentrate · 1.25 ml; 20 mg/ml (300 mg total) infusion concentrate · 15 ml. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Imjudo?＋
Catalogue records currently name: AstraZeneca GmbH GB Spezialvertrieb. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Imjudo?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Imjudo, payment request, stock guarantee or binding offer.
06Can I buy Imjudo from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.